Imaging vessel wall biology to predict outcome in abdominal aortic aneurysm

Circulation: Cardiovascular Imaging

Volumn 8, Issue 1, 2014, Pages

  Golestani, Reza ^a,b   Razavian, Mahmoud ^a,b   Nie, Lei ^a,b   Zhang, Jiasheng ^a,b   Jung, Jae Joon ^a,b   Ye, Yunpeng ^a,b   De Roo, Michelle ^a,b   Hilgerink, Koen ^a,b   Liu, Chi ^a   Robinson, Simon P ^c   Sadeghi, Mehran M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Clinical Research   (United States)

Author keywords

Aneurysm; Inflammation; Matrix metalloproteinases; Molecular imaging

Indexed keywords

ANGIOTENSIN II; CD68 ANTIGEN; MATRIX METALLOPROTEINASE; RADIOPHARMACEUTICAL AGENT; RP 805; SODIUM CHLORIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD68 PROTEIN, MOUSE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; INFLAMMATION; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ABDOMINAL AORTA; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; AORTOGRAPHY; C57BL MOUSE; CHEMICALLY INDUCED; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE MODEL; ENZYME ACTIVATION; EVALUATION STUDY; FEASIBILITY STUDY; MALE; METABOLISM; MOLECULAR IMAGING; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; TIME FACTOR; TRANSGENIC MOUSE;

ANGIOTENSIN II; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; AORTOGRAPHY; BIOMARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME ACTIVATION; FEASIBILITY STUDIES; MALE; MATRIX METALLOPROTEINASES; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR IMAGING; MULTIMODAL IMAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928040319     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.114.002471     Document Type: Article

References (38)

1. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8:92-102. doi: 10.1038/nrcardio.2010.180.
2. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat Rev Cardiol. 2009;6:543-552. doi: 10.1038/nrcardio.2009.102.
3. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-e654. doi: 10.1161/CIRCULATIONAHA.106.174526.
4. Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, Sicard GA, Timaran CH, Upchurch GR Jr, Veith FJ. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg. 2009;50:880-896. doi: 10.1016/j.jvs.2009.07.001.
5. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanning to the evaluation of abdominal aortic aneurysm. Semin Vasc Surg. 2004;17:144-153.
6. Kotze CW, Groves AM, Menezes LJ, Harvey R, Endozo R, Kayani IA, Ell PJ, Yusuf SW. What is the relationship between 18F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nucl Med Mol Imaging. 2011;38:1493-1499. doi: 10.1007/s00259-011-1799-8.
7. Truijers M, Kurvers HA, Bredie SJ, Oyen WJ, Blankensteijn JD. In vivo imaging of abdominal aortic aneurysms: increased FDG uptake suggests inflammation in the aneurysm wall. J Endovasc Ther. 2008;15:462-467. doi: 10.1583/08-2447.1.
8. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein HH, Krause BJ. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg. 2008;48:417-423. doi: 10.1016/j.jvs.2008.03.059.
9. Courtois A, Nusgens BV, Hustinx R, Namur G, Gomez P, Somja J, Defraigne JO, Delvenne P, Michel JB, Colige AC, Sakalihasan N. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med. 2013;54:1740-1747. doi: 10.2967/jnumed.112.115873.
10. Tavakoli S, Zamora D, Ullevig S, Asmis R. Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18F-FDG PET imaging of atherosclerosis. J Nucl Med. 2013;54:1661-1667. doi: 10.2967/jnumed.112.119099.
11. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, Di Carli MF, Libby P. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol. 2011;58:603-614. doi: 10.1016/j.jacc.2011.03.044.
12. Sadeghi MM. 18F-FDG pet and vascular inflammation: time to refine the paradigm? [published online ahead of print June 13, 2014]. J Nucl Cardiol. Available at: http://link.springer.com/article/10.1007%2 Fs12350-014-9917-1. doi: 10.1007/s12350-014-9917-1.
13. Wilson WR, Anderton M, Choke EC, Dawson J, Loftus IM, Thompson MM. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2008;35:580-584. doi: 10.1016/j.ejvs.2007.12.004.
14. Wilson WR, Anderton M, Schwalbe EC, Jones JL, Furness PN, Bell PR, Thompson MM. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation. 2006;113:438-445. doi: 10.1161/CIRCULATIONAHA.105.551572.
15. Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, Edwards DS, Azure M, Sinusas AJ, Sadeghi MM. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation. 2008;118:1953-1960. doi: 10.1161/CIRCULATIONAHA.108.789743.
16. Razavian M, Zhang J, Nie L, Tavakoli S, Razavian N, Dobrucki LW, Sinusas AJ, Edwards DS, Azure M, Sadeghi MM. Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nucl Med. 2010;51:1107-1115. doi: 10.2967/jnumed.110.075259.
17. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, Dione DP, Cavaliere P, Chow C, Bourke BN, Hu XY, Azure M, Yalamanchili P, Liu R, Cheesman EH, Robinson S, Edwards DS, Sinusas AJ. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005;112:3157-3167. doi: 10.1161/CIRCULATIONAHA.105.583021.
18. Razavian M, Nie L, Challa A, Zhang J, Golestani R, Jung JJ, Robinson S, Sadeghi MM. Lipid lowering and imaging protease activation in atherosclerosis. J Nucl Cardiol. 2014;21:319-328. doi: 10.1007/ s12350-013-9843-7.
19. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep. 2011;59:1-126.
20. Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG; RESCAN Collaborators. Surveillance intervals for small abdominal aortic aneurysms: a meta-analysis. JAMA. 2013;309:806-813. doi: 10.1001/ jama.2013.950.
21. Golestani R, Sadeghi MM. Emergence of molecular imaging of aortic aneurysm: implications for risk stratification and management. J Nucl Cardiol. 2014;21:251-267.
22. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994. doi: 10.1161/01.ATV.0000214999.12921.4f.
23. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
24. Kotze CW, Menezes LJ, Endozo R, Groves AM, Ell PJ, Yusuf SW. Increased metabolic activity in abdominal aortic aneurysm detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg. 2009;38:93-99. doi: 10.1016/j.ejvs.2008.12.016.
25. Sadat U, Taviani V, Patterson AJ, Young VE, Graves MJ, Teng Z, Tang TY, Gillard JH. Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of abdominal aortic aneurysms-a feasibility study. Eur J Vasc Endovasc Surg. 2011;41:167-174. doi: 10.1016/j.ejvs.2010.08.022.
26. Richards JM, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, Dweck M, Wallace W, McKillop G, Chalmers RT, Garden OJ, Newby DE. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging. 2011;4:274-281. doi: 10.1161/CIRCIMAGING.110.959866.
27. Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, Sadat U, Howarth SP, Gillard JH. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol. 2009;29:1001-1008. doi: 10.1161/ ATVBAHA.108.165514.
28. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011;278:28-45. doi: 10.1111/j.1742-4658.2010.07920.x.
29. Kaijzel EL, van Heijningen PM, Wielopolski PA, Vermeij M, Koning GA, van Cappellen WA, Que I, Chan A, Dijkstra J, Ramnath NW, Hawinkels LJ, Bernsen MR, Löwik CW, Essers J. Multimodality imaging reveals a gradual increase in matrix metalloproteinase activity at aneurysmal lesions in live fibulin-4 mice. Circ Cardiovasc Imaging. 2010;3:567-577. doi: 10.1161/CIRCIMAGING.109.933093.
30. Sheth RA, Maricevich M, Mahmood U. In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis. 2010;212:181-187. doi: 10.1016/j.atherosclerosis.2010.05.012.
31. Bazeli R, Coutard M, Duport BD, Lancelot E, Corot C, Laissy JP, Letourneur D, Michel JB, Serfaty JM. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2010;45:662-668. doi: 10.1097/RLI.0b013e3181ee5bbf.
32. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612. doi: 10.1172/JCI7818.
33. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432. doi: 10.1172/JCI38136.
34. Bruemmer D, Daugherty A, Lu H, Rateri DL. Relevance of angiotensin II-induced aortic pathologies in mice to human aortic aneurysms. Ann N Y Acad Sci. 2011;1245:7-10. doi: 10.1111/j.1749-6632.2011.06332.x.
35. Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins CS, Gerszten RE, Pittet MJ, Swirski FK, Weissleder R. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol. 2011;31:750-757. doi: 10.1161/ATVBAHA.110.221499.
36. Kitagawa T, Kosuge H, Chang E, James ML, Yamamoto T, Shen B, Chin FT, Gambhir SS, Dalman RL, McConnell MV. Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography. Circ Cardiovasc Imaging. 2013;6:950-956. doi: 10.1161/CIRCIMAGING.113.000234.
37. Klink A, Heynens J, Herranz B, Lobatto ME, Arias T, Sanders HM, Strijkers GJ, Merkx M, Nicolay K, Fuster V, Tedgui A, Mallat Z, Mulder WJ, Fayad ZA. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol. 2011;58:2522-2530. doi: 10.1016/j.jacc.2011.09.017.
38. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57-63. doi: 10.1016/j.atherosclerosis.2011.03.006.